Predicting the next round of drugs for Medicare price negotiation
There is uncertainty regarding which brand-name prescription drugs will have their prices negotiated by Medicare in 2025. This Viewpoint analyzes the process that will be used to select the next 15 drugs for price negotiation.
Authors
- Matthew Vogel (ORCID: https://orcid.org/0009-0005-5216-444X)
- Rena M. Conti (ORCID: https://orcid.org/0000-0002-4190-1839)
- Adam Tellier
Institutions
- Boston University (US)
- Harvard University (US)
- John F. Kennedy University (US)
Publication Details
- Journal
- Science Translational Medicine
- Published
- 2024-12-04
- DOI
- https://doi.org/10.1126/scitranslmed.adq5711
- Citations
- 1
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 1.13